Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Prospective Exploratory Study of Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Postoperative Recurrence of Pancreatic Cancer

NCT04902261 is registered in ClinicalTrials.gov with Changhai Hospital as lead sponsor.

NCT NCT04902261
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04902261 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Prospective Exploratory Study of Tislelizumab Combined With Nab-paclitaxel and Gemcitabine for Postoperative Recurrence of Pancreatic Cancer
Lead sponsor
Changhai Hospital
Phase
Phase 2
Overall status
Unknown status
Start date
November 20, 2020
Completion date
November 20, 2023
Enrollment
140 (estimated)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

recurrent pancreatic cancer